Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Monday, May 19th, 2008.

 

Sponsors

Archive for May 19th, 2008

Pediatricians fear it’s just a matter of time before a measles outbreak hits Colorado, in part because some parents refuse or neglect to vaccinate their children.

So far this year, there have been 64 confirmed cases of measles in nine states, according to the U.S. Centers for Disease Control and Prevention. That’s the highest number in the same period since 2001.

In four of the states, including Arizona, the CDC characterized the cases as outbreaks, in which at least three cases are linked by time or place.

The disease was brought into the U.S. from abroad this year, and health ex- perts are troubled that it spread when it got here. Dr. Bernadette Albanese, medical director of the El Paso County Department of Health and Environment, said that could indicate a weakening of the nation’s “herd immunity,” in which a population’s immunization is so widespread, a disease essentially has nowhere to go.

Measles is seldom fatal, but it can require hospitalization for a child and lead to serious complications such as pneumonia, ear infections and encephalitis. Symptoms include a high fever, puffy eyes, a runny nose and a rash.

Vaccinations are credited with dramatically decreasing what were once common and often fatal diseases. Ironically, though, the rarity of such diseases is why some parents don’t get their children immunized.

Doctors say the recent spike in cases illustrates what they’ve long preached about childhood shots: The diseases haven’t gone away, and it’s the immunizations that keep them contained.

“I’m worried about our measles immunization rate,” said Dr. Robert Brayden, a pediatrician at the Child Health Clinic at The Children’s Hospital in Aurora and head of the Colorado Children’s Immunization Coalition. “When our rate falls, we can be virtually guaranteed that we will have measles re-enter our population. It is worldwide, extremely contagious, and it is just a plane ride away.”

The cases this year reflect that. Ten of the patients who contracted the disease got it abroad; the rest appear to have caught it from them.

Measles has spread at schools, child care centers, hospitals and even a doctor’s office waiting room, Albanese said.

Measles is more contagious than many viruses. It doesn’t take a cough in the face or physical contact. Sitting across a room from someone for just a few minutes can be enough to contract the disease.

“This is really, from a public health standpoint, an alarming issue,” said Albanese. “If we don’t catch up on immunizations, this is going to continue, and we will see it in Colorado eventually.”

The last case of measles in El Paso County was in 1992, the health department said. The last case in Colorado was in Boulder County in 2006.

Two El Paso County adults were exposed to the Arizona outbreak, she said, but they were vaccinated and did not contract the disease.

All but one of the confirmed cases in the U.S. occurred in people who were not immunized or whose status was unknown, the CDC reported.

Nearly a quarter of Colorado children do not have documented immunizations for measles or other vaccine-preventable diseases, said Brayden. That number is roughly equal to the national average and includes poor families that don’t get routine health care.

But a few parents are simply saying no to vaccines.

Of the 21 cases of measles in the U.S. this year in people 16 months old to 19 years old — the age group targeted for required vaccinations — two-thirds were exempted for religious or personal beliefs.

All but two states allow people to opt out of immunization requirements for school on religious grounds; Colorado is one of about 20 states that also allow exemptions on philosophical grounds. Parents can sign “personal belief” exemptions without saying what those beliefs are.

One study in the Journal of the American Medical Association suggested Colorado’s personal-belief exemption was partly to blame for the state’s high pertussis rate, one of the worst in the nation.

Of Colorado’s unvaccinated children, Brayden said about 2 percent were exempted for personal beliefs.

Pediatricians say one recurring concern is parents’ fear of serious side effects, chiefly autism.

“They are almost always poorly informed people who have strong opinions on the subject,” said Dr. Fred Cox, who works at one of Memorial Health System’s two pediatric urgent care clinics. “I’m very much pro-immunization, and it distresses me greatly when I see people who refuse immunizations. They’ve generally been misled by some of these crackpot Web sites.”

More than a dozen studies in multiple countries have researched the safety of today’s vaccines, especially the measles, mumps and rubella vaccine. Included is research from the Institute of Medicine, a prestigious group of independent scientists whose work is analogous to Consumer Reports for the nonscientific community.

None of the studies has found links to autism or other serious side effects.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

(Audio News Release)

NUTLEY, N.J. — On May 19th, actor and author Christopher Kennedy Lawford will join advocates, clinicians and patients to observe the first International World Hepatitis Day in an effort to bring global attention to viral hepatitis, a disease that infects a staggering 500 million, that’s 1 in 12 people worldwide.1[1] In the United States alone, 4 million people are infected with hepatitis C2[2]- far more than people infected with HIV/AIDS.3[3] Christopher Kennedy Lawford says…

"In 2001, I was diagnosed with hepatitis C. I had no idea I might have it and was lucky my physician tested me. After successfully completing treatment for hepatitis C, I have been virus free for over six years." "Hepatitis C is a silent epidemic in this country. If I can do some good, with Roche, and other advocates to raise awareness about this disease; I’m all for that!"

FOR MORE INFORMATION ABOUT HEPATITIS C VISIT HEP-C-STAT-DOT-COM. (http://www.hepcstat.com)

1 ([1]) Hepatitis C Council of South Africa, "Information About Hepatitis Awareness Week 2008," available online at http://www.hepccouncilsa.asn.au/. Last accessed on April 23, 2008.

2 ([2]) Centers for Disease Control and Prevention, "Viral Hepatitis C Fact Sheet," available online at http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm. Last accessed on April 23, 2008.

3 ([3]) The Kaiser Family Foundation, "HIV/AIDS Policy Fact Sheet" available at http://www.kff.org/hivaids/upload/3029-08.pdf. Last accessed on May 5, 2008.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

- RDEA594 Data to Be Presented at the 2008 Annual European Congress of Rheumatology Organized by the European League Against Rheumatism (EULAR) -

- Initiation of Phase 1 Human Study of RDEA594 Planned in Second Half of 2008 -

SAN DIEGO, May 19 /PRNewswire-FirstCall/ — Ardea Biosciences, Inc. today announced the identification of its lead development candidate for the treatment of patients with gout, RDEA594. Gout is a painful and debilitating disease that is caused by abnormally elevated levels of uric acid in the blood stream. RDEA594 is a major metabolite in both humans and animals of RDEA806, the Company’s lead human immunodeficiency virus (HIV) development candidate. RDEA594 does not have significant antiviral activity, but is believed to be responsible for essentially all of the uric acid lowering effects seen with RDEA806. Robust uric acid-lowering effects have been observed following administration of RDEA806 in Phase 1 and Phase 2 clinical trials that included over 100 subjects.

Based on extensive in vitro and in vivo experiments, the Company believes it has elucidated the mechanism by which RDEA594 lowers serum uric acid levels. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1 transporter-mediated uptake of uric acid ex vivo and increases uric acid excretion in animal models. These effects are believed to result in the lowering of serum uric acid observed with RDEA806. URAT1 is a specific urate transporter expressed in the kidney responsible for regulation of uric acid levels, and is a validated target for treatment of hyperuricemia and gout.

"Gout represents a major medical challenge in the United States and throughout the world, with millions of people affected by this debilitating condition," said Barry D. Quart, PharmD, Ardea Biosciences’ President and CEO. "With the designation of RDEA594 as our clinical candidate for the treatment of gout, we now expect to have five novel candidates in clinical testing during the second half of 2008, positioning us with the potential to have a broad-based, late-stage pipeline in 2009. This finding also allows us to focus our future development efforts with RDEA806 on the treatment of HIV."

The Company plans to initiate a Phase 1 clinical study of RDEA594 in the second half of this year. As previously announced, the Company also plans to conduct a Phase 2 proof-of-concept clinical study in patients with gout, to confirm RDEA594’s activity in the target population using its prodrug, RDEA806. This study is on track to be initiated in the second quarter of this year.

  The EULAR presentation details are as follows:

   Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CEST
   Title: Safety and Uric Acid Lowering Effect in Humans Following Multiple
    Doses of RDEA806, A Novel Prodrug for the Potential Treatment of
    Hyperuricemia
    Location: Le Palais de Congres de Paris - Level 1 (Abstract # THU0356)

   Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CEST
   Title: Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans
    Following Multiple Doses of its Prodrug, RDEA806
   Location: Le Palais de Congres de Paris - Level 1 (Abstract # THU0357)

  About Gout

An estimated 3-5 million people in the United States suffer from gout, which is the most common form of inflammatory arthritis in men over 40. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connective tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options, and a number of adverse effects are associated with current therapies. No new therapies have been approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years.

About RDEA594

RDEA594 is a development candidate that has potential for treating gout patients with hyperuricemia. RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 studies with RDEA806 in healthy volunteers, increased urinary excretion of uric acid was observed in the first 24 hours after dosing, with statistically significant, exposure-dependent, decreases in serum uric acid of 35% to 50% observed following 10-14 days of dosing. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1-mediated uptake of uric acid ex vivo and is believed to be the active moiety responsible for the uric acid-lowering effects of RDEA806. Approximately 90% of hyperuricemic patients are considered to be under-excretors of uric acid, so increasing excretion may provide the most physiologically appropriate treatment. RDEA594 does not have significant antiviral activity.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

BLUE BELL, Pa. — VGX Pharmaceuticals announced today that it has submitted two separate investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-3100 and VGX-3400. Both candidate vaccines are based on VGX’s SynCon[TM] vaccine technology, and they have been developed using VGX’s integrated DNA Vaccines and Therapies Platform.

VGX-3100 is a DNA-based therapeutic vaccine that has the potential to treat cervical cancer caused by the human papilloma virus (HPV). VGX-3100 utilizes synthetic consensus sequences based on HPV antigens that offer coverage across different viral sub-types (types 16 and 18), which could potentially treat 71% of all cervical cancers. Although prophylactic vaccines for HPV, including Merck’s Gardasil[R] and GSK’s Cervarix[TM], have been recently approved, no therapeutic vaccine for HPV has been approved to date. Furthermore, studies suggest that these approved prophylactic vaccines do not have any therapeutic effects in women who are already infected with HPV.

VGX-3400 is a SynCon[TM] DNA-based preventative vaccine targeting avian influenza (AI). In pre-clinical studies, vaccination with VGX-3400 generated protective levels of hemagglutination inhibition (HAI) titers in 100% of the immunized animals in five separate animal models - mice, ferrets, rabbits, pigs, and rhesus monkeys. Vaccination with VGX-3400 also protected 100% of the animals from an unmatched, pathogenic H5N1 virus challenge in mouse and ferret models. VGX-3400 also induced significant levels of antigen-specific CD8+ killer T cell responses.

"Filing of these INDs with the FDA marks a significant milestone for our Company," stated Dr. J. Joseph Kim, President and Chief Executive Officer. "Using our vertically integrated product development platform, we have taken three independent product programs from ‘Bench to IND filing’ within 12 months. These accomplishments demonstrate the potential and efficiency of our product development platform."

VGX Pharmaceuticals’ SynCon[TM] DNA vaccine antigens are designed by aligning numerous primary sequences and choosing the most common and/or relevant amino acid at each site using high-powered and patented approaches. The gene sequences are then further optimized for expression and immunogenicity. The SynCon[TM] DNA vaccines in combination with the CELLECTRA[R] delivery device provide greater levels of cross-reactive immune responses than those produced by more traditional vaccines. In pre-clinical animal studies, delivery of both VGX-3100 and VGX-3400 was improved with the CELLECTRA[R] device.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company’s clinical development programs include PICTOVIR[TM] for HIV infection, which is in Phase II clinical trials, PENNVAX[TM]-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, the Company has filed INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon[TM] DNA-based product candidates, the CELLECTRA([R]) delivery device, and efficient cGMP plasmid manufacturing facilities. The cGMP facilities are used for VGX’s own product supplies and for contract manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from "bench-to-IND filing", within 1 year. The product candidates and technology programs are protected by the Company’s extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

LONDON (AFP) — The European Commission has granted the first licence to market a vaccine in preparation for a pandemic of H5N1 bird flu in Europe, British pharmaceutical firm GlaxoSmithKline said on Monday.

The ruling from the European Medicines Agency (EMEA) allows GSK to sell Prepandrix, which targets the most virulent strain of the virus that can be fatal to humans, in all 27 European Union member states.

“This vaccine marks a significant step in the world’s ability to cope with an influenza pandemic,” GSK chief executive Jean-Pierre Garnier said.

The company said the vaccine is based on the strain of H5N1 currently circulating, which the World Health Organisation said on April 30 has killed 241 people, mainly in southeast Asia, since 2003.

Prepandrix is based on the Vietnam strain and been …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

PARIS (AFP) — New ideas, young talent and injections of money are needed to invigorate the war against AIDS, top experts said here Monday at a review of medical progress since the human immunodeficiency virus (HIV) was discovered 25 years ago.

Men and women in the front line of the combat said there had been some remarkable successes in fighting AIDS.

They hailed the swift identification of the pathogen that causes acquired immunodeficiency syndrome (AIDS) and the advent of the “triple cocktail” of drugs in the mid-1990s that transformed a death sentence into a manageable disease.

But they also spoke of cruel setbacks.

These include the search for a vaccine — the only way of stopping the global pandemic — and an HIV-blocking vaginal gel to shield women.

Such failures show basic questions remain to be answered about HIV’s shape-shifting properties and its stealthy invasion of immune cells, they said. …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

First Treatment Success against a Non-Enveloped Virus</p>

WEST HAVEN, Conn. — NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it has received positive initial results from the animal trials of its drug candidates for the treatment of epidemic keratoconjunctivitis (EKC), a severe viral infection of the eye. Evidence of significant effectiveness was clinically observed in treated infected eyes.

"We were very pleased with the rapid response to treatment, and we had the opportunity to observe the excellent clinical response ourselves," said Eugene Seymour, MD, MPH, CEO of the Company. "The clinical results we observed are far superior to any data reported in the literature," said Anil R. Diwan, PhD, President of the Company.

The EKC study which is designed with a duration of four weeks, is currently in progress at a major medical center. Analysis of biological samples is expected to take several weeks following the completion of the study. The Company plans to make preliminary results available publicly as they are obtained.

There are approximately 5 million cases annually of this disease in the US, Europe and Japan. No adequate treatment exists at present. The infection causes severe pain, blurriness of vision and occasional blindness. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the Company projects the market for EKC and viral conjunctivitis may be several billion dollars annually.

The Company has now shown that two of its broad-spectrum nanoviricide drug candidates have excellent efficacies against substantially different virus types. We have now shown these nanoviricides to be very effective against certain non-enveloped viruses such as the EKC-causing adenovirus. Previously we have shown them to be highly effective against common influenza, bird flu (H5N1), rabies, and Ebola virus.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company’s novel nanoviricide[TM] class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company’s research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management’s Discussion and Analysis" section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

- IND or foreign regulatory equivalent filing anticipated in 1Q 2009 -

PRINCETON, N.J., May 19 /PRNewswire-FirstCall/ — Pharmasset, Inc. has nominated PSI-7851 as a lead development candidate for the treatment of chronic hepatitis C virus (HCV). PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that is being advanced into Good Laboratory Practice (GLP) animal toxicity studies required for submission of an Investigational New Drug (IND) application with the FDA or an equivalent foreign regulatory filing. PSI-7851 has demonstrated in vitro potency that is approximately 15- to 20-fold greater than the in vitro potency of R7128, a nucleoside analog polymerase inhibitor of HCV that Pharmasset is developing through its collaboration with Roche.

"Our in-house research team has, once again, discovered a new potential product candidate for the treatment of chronic HCV," stated Dr. Michael Otto, Pharmasset’s Chief Scientific Officer. "Our goal continues to be the identification of anti-HCV compounds with improved potency, equivalent or improved safety and oral bioavailability. In addition, we have focused on increasing intrahepatic triphosphate levels, which may lead to a higher level of active drug in the liver. We anticipate completing the required animal toxicity studies and filing an IND in the first quarter of 2009."

Nucleotide analogs have shown the ability to deliver higher levels of the active triphosphate form of the drug into infected cells. PSI-7851 has demonstrated in vitro anti-HCV activity with EC90 values of 0.31 +/- 0.12 uM, which is approximately 15- to 20-fold more potent than the active metabolite of R7128, PSI-6130. In vitro studies of PSI-7851 have not shown evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Early animal studies indicate that PSI-7851 can achieve concentrations of active triphosphate in the liver of up to 1,000 times higher than PSI-6130 at equivalent doses.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

  Pegasys(R) and Copegus(R) are registered trademarks of Roche.

  Contact
  Alan Roemer, Vice President
  Investor Relations & Corporate Communications
  alan.roemer@pharmasset.com
  Office: (609) 613-4125

  Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that our results from early studies with PSI-7851 are not repeated in future studies, the risk that we are not able to gather the data and information necessary to, or that we otherwise cannot, file an IND for PSI-7851, the risk that PSI-7851 never becomes a product candidate or is never successfully developed and commercialized, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of any or all of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration studies for clevudine, the risk that our collaboration with Roche will not continue or will not be successful, the risk that any one or more of our product candidates will not be successfully developed and commercialized and the risk that we will not be able to further develop any of the compounds from the new series of anti-HCV molecules currently being investigated by us. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

VShield Software Corp. (PINKSHEETS: VSHE) today
announced that it will be adding a new suite of tools specifically
targeting malicious software in the form of viruses, spam, spyware, worms
and Trojan Horses. The new tools will be tightly integrated into the
VSArmour kernel and will act in conjunction with its other security systems
and features. Although the present data treatment and access security does
not allow for the retransmission of valuable data files, VShield Software
felt that the introduction of world class extensions to its software would
further deter any attacks and allow the network managers to strengthen and
tune their security further. VShield Software will be announcing which
heuristic recognitions systems it will be incorporating for the recognition
of its antivirus and anti spam toolsets and once completed they will be
from a world recognized vendor and best in class. The combined software
suites will be the safest product on the market today and will allow the
network security specialist the tools they have been waiting for.

“This integration of the new malicious software recognition and
neutralization technology will allow our clients worldwide to have the most
secure working environments possible. No virus, worm, hacker, inside or
outside spy, disgruntled employee, Trojan horse, scam or lost hard disk
will ever allow sensitive data to fall into the wrong hands. We intend to
tame the wild online Internet, stop inside and outside data theft and
ensure that no credit card information is stolen from any of our clients
ever again. IT professionals can now sleep again as we will put back the
private in private networks and slam the door shut on hackers and thieves,”
stated Patrick Burke.

About VShield Software Corp.

The company designs, produces, markets and sells leading edge computer
security software programs that feature advanced software development and
technologies that are superior to other products on the market. All of the
Company’s security systems are based on previously proven and field tested
large commercial security systems. These systems are based on hiding,
disguising and encrypting various levels of files maintained on a computer
such that an intruder is unable to obtain information from a desired file.
This is unlike existing ‘firewall’ systems now on the market which are
focused on keeping intruders from gaining unauthorized entry to a computer.
Where applicable, products are patent and copyright protected in both
Canada and the United States.

This news release may contain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Act of 1934, as amended; such statements are subject to
risks and uncertainties that could cause actual results to vary materially
from those projected in the forward-looking statements. The Company may
experience significant fluctuations in operating results due to a number of
economic, competitive and other factors. These factors could cause
operations to vary significantly from those in prior periods, and those
projected in forward-looking statements. Information with respect to these
factors which could materially affect the Company and its operations are
included on certain forms the Company files with the Securities and
Exchange Commission.

Distributed by Filing Services Canada and retransmitted by Marketwire

Contact:

VShield Software Corp.
By Web: Email Contact
Digital Assistant: (302) 336-9736

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Beakers To The Rescue

May 19, 2008

Scientists say a new green revolution could head off future food crises.

Pity the papaya. odd-shaped and orange-fleshed, it lacks the iconic status of the apple or the stage presence of the banana. Lately, though, it has become something of an agronomic superstar. Last month a team of international researchers led by the University of Hawaii finished mapping the genome of a variety of papaya engineered to withstand ringspot virus. Ringspot is a killer; it nearly wiped out Hawaii’s $17 million-a-year papaya industry. Then, in the late ’90s, scientists came to the rescue by plucking a gene from the virus itself and splicing it into the papaya plant, like a vaccine. Today, Hawaii’s papaya groves are flourishing and, with the genome in hand, scientists now believe they will be able to replicate similar harvest-saving technology for different crops around the world. Chalk one up for the second green revolution: the …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx